Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00860158 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
A Phase 2 study, sponsored by Noah Hahn, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00860158 is a Phase 2 study that was terminated before completion, run by Noah Hahn, M.D.. The registered enrollment target is 1 participants.
The verdict
NCT00860158, a Phase 2 study, was terminated before completion, sponsored by Noah Hahn, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
Interventions
- PROCEDURE Radical Prostatectomy
- DRUG Dasatinib
- DRUG Leuprolide Acetate (LHRH Analogue)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00860158
The ClinicalTrials.gov registry entry for NCT00860158 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noah Hahn, M.D., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radical Prostatectomy is the first listed.
NCT00860158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00860158 about?
NCT00860158 is a clinical study titled "Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer". This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
What is the current status of trial NCT00860158?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2009-03. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00860158?
The interventions under investigation include: Radical Prostatectomy (PROCEDURE), Dasatinib (DRUG), Leuprolide Acetate (LHRH Analogue) (DRUG).
Who is sponsoring clinical trial NCT00860158?
This trial is sponsored by Noah Hahn, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.